AstraZeneca’s Farxiga Approved for Heart Failure in Type 2 Diabetes Patients

AstraZeneca received the FDA’s approval for Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

The first-in-class, oral once-daily drug is indicated as both a monotherapy and as a combination therapy for improving glycemic control, in addition to weight loss and reducing blood pressure, alongside dieting and exercise in adult type 2 diabetes patients.

The drug “now offers the opportunity for physicians to act sooner and reduce the risk of hospitalization for heart failure,” an AZ spokesperson said.